WHO ICTRP trial
A double-blind, randomized Phase II study to determine efficacy and safety of…
EUCTR2005-000317-35-DE · EU Clinical Trials Register · Not Recruiting
Key facts
| Trial ID | EUCTR2005-000317-35-DE |
|---|---|
| Public title | A double-blind, randomized Phase II study to determine efficacy and safety of oral treatment with BIBF 1120 ES 250 mg twice daily versus 150 mg twice daily in patients suffering from advanced non-small-cell lung cancer. - - |
| Scientific title | A double-blind, randomized Phase II study to determine efficacy and safety of oral treatment with BIBF 1120 ES 250 mg twice daily versus 150 mg twice daily in patients suffering from advanced non-small-cell lung cancer. - - |
| Primary sponsor | Boehringer Ingelheim Pharma GmbH & Co. KG |
| Registry | EU Clinical Trials Register |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Countries | Germany |
| Conditions | Relapsed non-small-cell lunger cancer patients stage IIIB and stage IV after previous treatment with platinum- or non-platinum based chemotherapy MedDRA version: 7.1 Level: PT Classification code 10061873 |
| Interventions | Product Name: BIBF 1120 ES 50 mg Product Code: BIBF 1120 ES Pharmaceutical Form: Capsule, soft INN or Proposed INN: Not available CAS Number: - Current Sponsor code: BIBF 1120 ES Other descriptive name: Not available Concentration unit… |
| Registration date | Nov 1, 2006 |
| Target size | 70 |
| Secondary IDs | 1199.10;not available |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: